Finepoint Capital’s Travere Therapeutics TVTX Stock Holding History

Finepoint Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,782,267	Closed	-$24.9M	–	28
2024 Q3	$24.9M	Buy	1,782,267 +5,539	+0.3%	+$57.7K	1.81%	8
2024 Q2	$14.6M	Buy	1,776,728 +127,507	+8%	+$859K	4.15%	10
2024 Q1	$12.7M	Buy	1,649,221 +213,900	+15%	+$1.8M	3.26%	15
2023 Q4	$12.9M	Buy	1,435,321 +539,500	+60%	+$3.93M	4.07%	15
2023 Q3	$8.01M	Buy	895,821 +134,100	+18%	+$1.89M	3.99%	13
2023 Q2	$11.7M	Sell	761,721 -113,500	-13%	-$2.06M	4.05%	16
2023 Q1	$19.7M	Sell	875,221 -151,079	-15%	-$3.21M	7.52%	1
2022 Q4	$21.6M	Sell	1,026,300 -2,575	-0.3%	-$54.6K	6.98%	1
2022 Q3	$25.4M	Buy	1,028,875 +444,575	+76%	+$11.5M	8.34%	1
2022 Q2	$14.2M	Buy	+584,300	New	+$14.7M	4.9%	11

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Finepoint Capital's TVTX Position: Q4 2024 in Review

Finepoint Capital sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 1,782,267 shares — an estimated $24.9M sold.

Finepoint Capital first reported a position in TVTX in Q2 2022 and held it in 10 quarters. The position peaked at $25.4M in Q3 2022. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

Finepoint Capital reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
Finepoint Capital sold 1,782,267 Travere Therapeutics shares in Q4 2024, an estimated $24.9M.
Finepoint Capital first reported a position in Travere Therapeutics in Q2 2022 and held it in 10 quarters.
Finepoint Capital's Travere Therapeutics position peaked at $25.4M in Q3 2022.
197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Finepoint Capital's 13F filing for Q4 2024, filed 13 Feb 2025.